Pharmacogenetics of chemotherapy-induced nausea and vomiting

Shigekazu Sugino, Piotr K. Janicki

Research output: Contribution to journalReview articlepeer-review

16 Citations (Scopus)

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is associated with distressing adverse effects observed in patients during cytotoxic chemotherapy. One of the potential factors explaining suboptimal response to currently used antiemetics is variability in genes encoding enzymes and proteins that play a role in the action of antiemetic drugs. Pharmacogenomics studies of CINV are sparse and focus mainly on polymorphisms associated with serotonin receptor, drug metabolism and drug transport. Currently, the role of pharmacogenetics in mechanisms of CINV has not been fully unraveled, and it is premature to implement results of pharmacogenetic association studies of antiemetic drugs in clinical practice. More uniform studies, with genetic profiles and biomarkers relevant for the proposed target and transporter mechanisms, are needed.

Original languageEnglish
Pages (from-to)149-160
Number of pages12
JournalPharmacogenomics
Volume16
Issue number2
DOIs
Publication statusPublished - 2015 Jan 1
Externally publishedYes

Keywords

  • 5-HT receptor
  • antiemetics
  • chemotherapy-induced nausea and vomiting
  • cytochrome P450
  • genetic variants
  • neurokinin 1 receptor
  • pharmacogenetics
  • single nucleotide polymorphism
  • substance P

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Pharmacogenetics of chemotherapy-induced nausea and vomiting'. Together they form a unique fingerprint.

Cite this